Skip to main content
Erschienen in: Endocrine 2/2012

01.04.2012 | Original Article

Clinical and radiological findings in macroprolactinemia

verfasst von: Serhat Isik, Dilek Berker, Yasemin Ates Tutuncu, Ufuk Ozuguz, Ferhat Gokay, Gonul Erden, Hatice Nursun Ozcan, Ferit Kerim Kucukler, Yusuf Aydin, Serdar Guler

Erschienen in: Endocrine | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Hyperprolactinemia is the most common abnormality of the hypothalamic–pituitary axis. The aim of this study was to investigate the clinical and radiological features of patients with macroprolactinemia. The study population consisted of patients with elevated serum prolactin (PRL) concentrations who presented to our Endocrinology outpatient clinic. Detection of macroprolactin (macroPRL) was performed using the polyethylene glycol precipitation method. Patients in which macroPRL made up more than 60% of total PRL levels were stratified into the macroPRL group, while the remaining patients were placed in the monomeric prolactin (monoPRL) group. A total of 337 patients were enrolled with a mean age of 33.8 ± 10.8 (16–66) years and a male/female ratio of 29/308. Eighty-eight of the patients (26.1%) had an elevated macroPRL level. The mean age in the monoPRL group was higher than in the macroPRL group (35.0 ± 10.1 vs. 30.7 ± 9.8, P = 0.016). The mean PRL levels (ng/ml) in the macroPRL and monoPRL groups were similar (168.0 ± 347.0 vs. 238.8 ± 584.9, P = 0.239). Frequency of amenorrhea, infertility, irregular menses, gynecomastia, and erectile dysfunction were also similar in both groups. More patients in the macroPRL group were asymptomatic compared to the monoPRL group (30.2 vs. 12.0%, P = 0.006). Compared to the macroPRL group, the monoPRL group had a higher frequency of galactorrhea (39.2 vs. 57.1%, P = 0.04) and abnormal magnetic resonance imaging findings (65.3 vs. 81.1%, P = 0.02). Elevated macroPRL levels should be considered a pathological biochemical variant of hyperprolactinemia that may present with any of the conventional symptoms and radiological findings generally associated with elevated PRL levels.
Literatur
1.
Zurück zum Zitat D.C Aron, J.W Findling, J.B Tyrrell, Hypothalamus and pituitary gland, in Basic and Clinical Endocrinology, 7th edn. by F.S. Greenspan, D.G Gardner (Lange Medical Books-McGraw Hill, New York 2004), pp. 106–175 D.C Aron, J.W Findling, J.B Tyrrell, Hypothalamus and pituitary gland, in Basic and Clinical Endocrinology, 7th edn. by F.S. Greenspan, D.G Gardner (Lange Medical Books-McGraw Hill, New York 2004), pp. 106–175
2.
Zurück zum Zitat O.M. Hauache, A.J. Rocha, A.C. Maia Jr., R.M. Maciel, J.G. Vieira, Screening for macroprolactinaemia and pituitary imaging studies. Clin. Endocrinol. (Oxf) 57, 327–331 (2002)CrossRef O.M. Hauache, A.J. Rocha, A.C. Maia Jr., R.M. Maciel, J.G. Vieira, Screening for macroprolactinaemia and pituitary imaging studies. Clin. Endocrinol. (Oxf) 57, 327–331 (2002)CrossRef
3.
Zurück zum Zitat H. Leslie, C.H. Courtney, P.M. Bell et al., Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J. Clin. Endocrinol. Metab. 86, 2743–2746 (2001)PubMedCrossRef H. Leslie, C.H. Courtney, P.M. Bell et al., Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J. Clin. Endocrinol. Metab. 86, 2743–2746 (2001)PubMedCrossRef
4.
Zurück zum Zitat J.G. Vieira, T.T. Tachibana, L.H. Obara, R.M. Maciel, Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin. Chem. 44, 1758–1759 (1998)PubMed J.G. Vieira, T.T. Tachibana, L.H. Obara, R.M. Maciel, Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin. Chem. 44, 1758–1759 (1998)PubMed
5.
Zurück zum Zitat M.R. Sánchez-Eixerés, M. Mauri, R. Alfayate et al., Prevalence of macroprolactin detected by Elecsys 2010. Horm. Res. 56, 87–92 (2001)PubMedCrossRef M.R. Sánchez-Eixerés, M. Mauri, R. Alfayate et al., Prevalence of macroprolactin detected by Elecsys 2010. Horm. Res. 56, 87–92 (2001)PubMedCrossRef
6.
Zurück zum Zitat T.P. Smith, A.M. Suliman, M.N. Fahie-Wilson, T.J. McKenna, Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J. Clin. Endocrinol. Metab. 87, 5410–5415 (2002)PubMedCrossRef T.P. Smith, A.M. Suliman, M.N. Fahie-Wilson, T.J. McKenna, Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J. Clin. Endocrinol. Metab. 87, 5410–5415 (2002)PubMedCrossRef
7.
Zurück zum Zitat S. Vallette-Kasic, I. Morange-Ramos, A. Selim et al., Macroprolactinemia revisited: A study on 106 patients. J. Clin. Endocrinol. Metab. 87, 581–588 (2002)PubMedCrossRef S. Vallette-Kasic, I. Morange-Ramos, A. Selim et al., Macroprolactinemia revisited: A study on 106 patients. J. Clin. Endocrinol. Metab. 87, 581–588 (2002)PubMedCrossRef
8.
Zurück zum Zitat B. Cavaco, V. Leite, M.A. Santos, E. Arranhado, L.G. Sobrinho, Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J. Clin. Endocrinol. Metab. 80, 2342–2346 (1995)PubMedCrossRef B. Cavaco, V. Leite, M.A. Santos, E. Arranhado, L.G. Sobrinho, Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J. Clin. Endocrinol. Metab. 80, 2342–2346 (1995)PubMedCrossRef
9.
Zurück zum Zitat V. Leite, H. Cosby, L.G. Sobrinho, M.A. Fresnoza, M.A. Santos, H.G. Friesen, Characterization of big, big prolactin in patients with hyperprolactinemia. Clin. Endocrinol. (Oxf) 37, 365–372 (1992)CrossRef V. Leite, H. Cosby, L.G. Sobrinho, M.A. Fresnoza, M.A. Santos, H.G. Friesen, Characterization of big, big prolactin in patients with hyperprolactinemia. Clin. Endocrinol. (Oxf) 37, 365–372 (1992)CrossRef
10.
Zurück zum Zitat T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. N. Am. 37(1), 67–99 (2008)CrossRef T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. N. Am. 37(1), 67–99 (2008)CrossRef
11.
Zurück zum Zitat A.O. Olukoga, J.W. Kane, Macroprolactinaemia: Validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin. Endocrinol. (Oxf) 51, 119–126 (1999)CrossRef A.O. Olukoga, J.W. Kane, Macroprolactinaemia: Validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin. Endocrinol. (Oxf) 51, 119–126 (1999)CrossRef
12.
Zurück zum Zitat A.M. Suliman, T.P. Smith, J. Gibney, T.J. McKenna, Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: Application of a new strict laboratory definition of macroprolactinemia. Clin. Chem. 49, 1504–1509 (2003)PubMedCrossRef A.M. Suliman, T.P. Smith, J. Gibney, T.J. McKenna, Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: Application of a new strict laboratory definition of macroprolactinemia. Clin. Chem. 49, 1504–1509 (2003)PubMedCrossRef
13.
Zurück zum Zitat K. Ichihara, K. Miyai, Detection of asymptomatic prolactinoma by a mass screening program. Rinsho Byori 38, 667–674 (1990)PubMed K. Ichihara, K. Miyai, Detection of asymptomatic prolactinoma by a mass screening program. Rinsho Byori 38, 667–674 (1990)PubMed
14.
Zurück zum Zitat T. Bjøro, L. Mørkrid, R. Wergeland et al., Frequency of hyperprolactinaemia due to large molecular weight prolactin (150–170 kD PRL) Scand. J. Clin. Lab. Invest. 55, 139–147 (1995)CrossRef T. Bjøro, L. Mørkrid, R. Wergeland et al., Frequency of hyperprolactinaemia due to large molecular weight prolactin (150–170 kD PRL) Scand. J. Clin. Lab. Invest. 55, 139–147 (1995)CrossRef
15.
Zurück zum Zitat M.N. Fahie-Wilson, S.G. Soule, Macroprolactinaemia: Contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann. Clin. Biochem. 34, 252–258 (1997)PubMed M.N. Fahie-Wilson, S.G. Soule, Macroprolactinaemia: Contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann. Clin. Biochem. 34, 252–258 (1997)PubMed
16.
Zurück zum Zitat Y.N. Sinha, Structural variants of prolactin: Occurrence and physiological significance. Endocr. Rev. 16, 354–369 (1995)PubMed Y.N. Sinha, Structural variants of prolactin: Occurrence and physiological significance. Endocr. Rev. 16, 354–369 (1995)PubMed
17.
Zurück zum Zitat C.R. Smith, M.R. Norman, Prolactin and growth hormone: molecular heterogeneity and measurement in serum. Ann. Clin. Biochem. 27, 542–550 (1990)PubMed C.R. Smith, M.R. Norman, Prolactin and growth hormone: molecular heterogeneity and measurement in serum. Ann. Clin. Biochem. 27, 542–550 (1990)PubMed
18.
Zurück zum Zitat S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, Endocrine Society Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011)PubMedCrossRef S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, Endocrine Society Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011)PubMedCrossRef
19.
Zurück zum Zitat J. Gibney, T.P. Smith, T.J. McKenna, The impact on clinical practice of routine screening for macroprolactin. J. Clin. Endocrinol. Metab. 90, 3927–3932 (2005)PubMedCrossRef J. Gibney, T.P. Smith, T.J. McKenna, The impact on clinical practice of routine screening for macroprolactin. J. Clin. Endocrinol. Metab. 90, 3927–3932 (2005)PubMedCrossRef
20.
Zurück zum Zitat F.F. Casanueva, M.E. Molitch, J.A. Schlechte et al., Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf) 65(2), 265–273 (2006)CrossRef F.F. Casanueva, M.E. Molitch, J.A. Schlechte et al., Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf) 65(2), 265–273 (2006)CrossRef
21.
Zurück zum Zitat I.R. Wallace, N. Satti, C.H. Courtney, H. Leslie, P.M. Bell, S.J. Hunter, D.R. McCance, B. Sheridan, A.B. Atkinson, Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J. Clin. Endocrinol. Metab. 95(7), 3268–3271 (2010)PubMedCrossRef I.R. Wallace, N. Satti, C.H. Courtney, H. Leslie, P.M. Bell, S.J. Hunter, D.R. McCance, B. Sheridan, A.B. Atkinson, Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J. Clin. Endocrinol. Metab. 95(7), 3268–3271 (2010)PubMedCrossRef
22.
Zurück zum Zitat T. Rand, E. Kink, M. Sator et al., MRI of microadenomas in patients with hyperprolactinemia. Neuroradiology 38, 744–746 (1996)PubMedCrossRef T. Rand, E. Kink, M. Sator et al., MRI of microadenomas in patients with hyperprolactinemia. Neuroradiology 38, 744–746 (1996)PubMedCrossRef
23.
Zurück zum Zitat A. Bayrak, P. Saadat, E. Mor, L. Chong, R.J. Paulson, R.Z. Sokol, Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil. Steril. 84, 181–185 (2005)PubMedCrossRef A. Bayrak, P. Saadat, E. Mor, L. Chong, R.J. Paulson, R.Z. Sokol, Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil. Steril. 84, 181–185 (2005)PubMedCrossRef
24.
Zurück zum Zitat G. Tamer, A. Telci, M. Mert, et al., Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine. (2011) G. Tamer, A. Telci, M. Mert, et al., Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine. (2011)
25.
Zurück zum Zitat P.E. Garnier, M.L. Aubert, S.L. Kaplan, M.M. Grumbach, Heterogeneity of pituitary and plasma prolactin in man: decreased affinity of “big” prolactin in a radioreceptor assay and evidence for its secretion. J. Clin. Endocrinol. Metab. 47, 1273–1281 (1978)PubMedCrossRef P.E. Garnier, M.L. Aubert, S.L. Kaplan, M.M. Grumbach, Heterogeneity of pituitary and plasma prolactin in man: decreased affinity of “big” prolactin in a radioreceptor assay and evidence for its secretion. J. Clin. Endocrinol. Metab. 47, 1273–1281 (1978)PubMedCrossRef
26.
Zurück zum Zitat A.D. Rogol, R.C. Eastman, T. Manolio, S.W. Rosen, Unusual heterogeneity of circulating prolactin in an acromegalic. J. Endocrinol. Invest. 4, 221–227 (1981)PubMed A.D. Rogol, R.C. Eastman, T. Manolio, S.W. Rosen, Unusual heterogeneity of circulating prolactin in an acromegalic. J. Endocrinol. Invest. 4, 221–227 (1981)PubMed
27.
Zurück zum Zitat F. Larrea, C. Villanueva, M. Carmen Cravioto, A. Escorza, O. del Real, Further evidence that big–big prolactin is preferentially secreted in women with hyperprolactinemia and normal ovarian function. Fertil. Steril. 44, 25–30 (1985)PubMed F. Larrea, C. Villanueva, M. Carmen Cravioto, A. Escorza, O. del Real, Further evidence that big–big prolactin is preferentially secreted in women with hyperprolactinemia and normal ovarian function. Fertil. Steril. 44, 25–30 (1985)PubMed
28.
Zurück zum Zitat N. Hattori, K. Ikekubo, T. Ishihara, K. Moridera, M. Hino, H. Kurahachi, Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. Eur. J. Endocrinol. 130, 438–445 (1994)PubMedCrossRef N. Hattori, K. Ikekubo, T. Ishihara, K. Moridera, M. Hino, H. Kurahachi, Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. Eur. J. Endocrinol. 130, 438–445 (1994)PubMedCrossRef
29.
Zurück zum Zitat D.L. Kleinberg, G.L. Noel, A.G. Frantz, Galactorrhea: A study of 235 cases including 48 with pituitary tumors. N. Engl. J. Med. 296, 589–600 (1977)PubMedCrossRef D.L. Kleinberg, G.L. Noel, A.G. Frantz, Galactorrhea: A study of 235 cases including 48 with pituitary tumors. N. Engl. J. Med. 296, 589–600 (1977)PubMedCrossRef
Metadaten
Titel
Clinical and radiological findings in macroprolactinemia
verfasst von
Serhat Isik
Dilek Berker
Yasemin Ates Tutuncu
Ufuk Ozuguz
Ferhat Gokay
Gonul Erden
Hatice Nursun Ozcan
Ferit Kerim Kucukler
Yusuf Aydin
Serdar Guler
Publikationsdatum
01.04.2012
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2012
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9576-9

Weitere Artikel der Ausgabe 2/2012

Endocrine 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.